Only a few drug makers are actively targeting medicines needed in poor countries

In this article, Ed Silverman of STAT news covers the results of the 2018 Access to Medicine Index: "A new report finds five large drug makers are doing most of the heavy lifting, but much of the R&D is focused on only five diseases, leaving many illnesses unaddressed."

The article refers to the pharmaceutical R&D priorities that have been identified for low- and middle-income countries and how companies are responding to these.